Opiant Pharmaceuticals Return on Equity

Opiant Pharmaceuticals (OPNT) currently reports a ROE of -163.34%. That is below the Healthcare sector average of 20.77%. Use the charts on this page to explore Opiant Pharmaceuticals's ROE history and peer comparisons.

Opiant Pharmaceuticals's ROE of -163.34% is lower than the Healthcare sector average of 20.77%. That is roughly 886.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Opiant Pharmaceuticals's current -163.34% should be judged against Healthcare norms (sector average: 20.77%) and against OPNT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -163.34%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for Opiant Pharmaceuticals, and consider following OPNT for alerts when major investors trade the stock.

Opiant Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows -163.34% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing OPNT with unrelated industries.